NCT01035255

GPTKB entity

Statements (27)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 Years to 65 Years
gptkbp:allocates Randomized
gptkbp:clinicalTrialPhase Phase 2
gptkbp:completedIn August 2011
gptkbp:conditionStudied Schizophrenia
gptkbp:enrollment 415
gptkbp:gender All
https://www.w3.org/2000/01/rdf-schema#label NCT01035255
gptkbp:intervention gptkb:drug
RO4917838
gptkbp:location gptkb:Asia
gptkb:Europe
gptkb:United_States
gptkbp:mask Double-blind
gptkbp:primaryOutcomeMeasure Change from baseline in PANSS total score at Week 6
gptkbp:purpose Treatment
gptkbp:recognizedBy gptkb:NCT01035255
gptkbp:secondaryOutcomeMeasure Change from baseline in CGI-S score at Week 6
gptkbp:sponsor gptkb:Hoffmann-La_Roche
gptkbp:startDate December 2009
gptkbp:status completed
gptkbp:studyType Interventional
gptkbp:title A Study of RO4917838 in Patients With Schizophrenia
gptkbp:url https://clinicaltrials.gov/ct2/show/NCT01035255
gptkbp:bfsParent gptkb:PARADIGM-HF
gptkbp:bfsLayer 6